Shares of Outlook Therapeutics Inc. (NASDAQ:OTLK) rose 4.7% on Tuesday following the company’s announcement that the U.S. Food and Drug Administration has accepted its resubmitted Biologics License Application for ONS-5010, marketed as LYTENAVA, intended to treat wet age-related macular degeneration (wet AMD).
The FDA classified the resubmitted BLA as a Class 1 review and assigned a Prescription Drug User Fee Act target action date of July 29, 2026. Outlook Therapeutics disclosed the regulator’s acceptance on Monday.
ONS-5010/LYTENAVA is an ophthalmic formulation of bevacizumab. If the FDA grants approval, the product would represent the first FDA-approved ophthalmic bevacizumab supported by standardized manufacturing, FDA-approved labeling, and pharmacovigilance, according to the company.
Commenting on the filing acceptance, Outlook’s Chief Executive Officer Bob Jahr said: "We are very pleased that the FDA has accepted our resubmitted BLA to review the labelling as part of the final step toward potential approval. This is great news for Outlook and the LYTENAVA team, patients and the retina community." The company made the quote public as part of its filing update.
Outlook Therapeutics already holds regulatory clearances for LYTENAVA outside the United States. The product has received Marketing Authorization from the European Commission in the European Union and from the Medicines and Healthcare products Regulatory Agency in the United Kingdom for the treatment of wet AMD. The company has begun commercial launches in Germany, Austria, and the U.K.
In parallel with the FDA review, Outlook has initiated pre-launch activities in the U.S. in anticipation of potential approval. The active ingredient, bevacizumab, is a recombinant humanized monoclonal antibody that binds to human vascular endothelial growth factor. By binding VEGF, the compound reduces endothelial cell proliferation and the formation of new blood vessels within the retina, the mechanism cited by the company.
Context and implications
The company’s announcement and the FDA acceptance of the resubmitted BLA corresponded with a modest intraday uptick in its stock price. The regulatory timeline established by the FDA sets a clear target date for a potential decision later in 2026. Outlook’s existing authorizations and initial European commercial rollouts position the company to pursue U.S. commercialization if the FDA grants approval.
Market reaction
Investor response to the filing acceptance was immediately visible in the share movement reported on Tuesday. The stock’s 4.7% rise followed the company’s disclosure, reflecting market focus on regulatory milestones for therapeutics addressing retinal disease.
Key points
- FDA accepted Outlook Therapeutics’ resubmitted BLA for ONS-5010/LYTENAVA and classified it as a Class 1 review with a target action date of July 29, 2026.
- LYTENAVA is an ophthalmic bevacizumab formulation; if approved in the U.S., it would be the first such FDA-approved product supported by standardized manufacturing, labeling, and pharmacovigilance.
- The product has already received Marketing Authorization in the EU and UK, and Outlook has initiated commercial launches in Germany, Austria, and the UK while starting U.S. pre-launch activities.
Risks and uncertainties
- Regulatory uncertainty remains until the FDA issues a final decision by the established target date; the company’s potential U.S. approval is not guaranteed.
- Commercial performance in the U.S. depends on eventual FDA approval; current revenue exposure in Europe and the U.K. does not ensure U.S. market success.
- Market volatility around regulatory milestones can affect the company’s stock price, as shown by the reported intraday move following the announcement.